In anticipation of future growth and product expansion, Gobiquity has added new members to its executive management team (Chief Technology Officer Bob Quinn) and board of directors (Welltok’s Chief Marketing Officer, Michelle Snyder). The company recently celebrated a milestone of 175,000+ children screened with its flagship product, GoCheck Kids™.
Gobiquity’s latest round of funding will help support product development and global expansion of its flagship product, GoCheck Kids™ mobile vision screener. Now surpassing 100,000 vision screenings, GoCheck Kids is changing the standard of care, enabling efficient detection and prevention of permanent vision loss.
Wander the AAP exhibition hall with Dr Schuman as he previews the best and brightest technology for the pediatric practice.
Gobiquity Mobile Health has officially launched GoCheck Kids on iOS, extending the ability of pediatricians and other primary care providers to effectively screen for amblyopia.
Gobiquity Mobile Health has launched the world’s first and only comprehensive vision screening app on iOS. Along with previous mobile photoscreening capabilities, the GoCheck Kids screening platform now includes digital visual acuity and personalized vision screening guidance, enabling clinically validated screening from the palm of a physician’s hand.
Early screenings can prevent amblyopia, the leading cause of childhood blindness, but less than 20% of preschool age children are tested for the condition.
Smartphone app may help pediatric specialists confirm a suspicion of amblyopia.
A new type of vision test for kids checks for a potentially debilitating disease in seconds.
Gobiquity CEO Andrew Burns talks about using GoCheck Kids to identify risk factors early, helping prevent more serious conditions and reduce healthcare costs.
Gobiquity Mobile Health™ will move from Aliso Viejo, CA to Scottsdale, AZ to join the growing number of bio-life science professionals in the city’s “Cure Corridor.”
Pediatricians now have a new way to screen for amblyopia, a leading cause of vision loss in children.
The authors of a new study examining the efficacy of a mobile smartphone vision-screening device that screens amblyopia risk factors (ARFs) in preschool children provided an analysis of their prospective study at AAPOS.
On Saturday, March 28, Dr. Robert Arnold will present a new study to discuss automated instrument-based photoscreeners that are designed to identify preschool children with amblyopia risk factors (ARFs).
Gobiquity CEO Andrew Burns presented Gobiquity’s flagship product GoCheck Kids at the 7th SXSW Accelerator Competition.
Gobiquity has been invited to present GoCheck Kids—an ingenious smartphone app that enables pediatricians to determine their patients’ risk of serious vision conditions—at the prestigious 2015 SXSW Accelerator Competition.
Andrew Schuman, MD, FAAP, provides a recap of his presentation from the 2014 American Academy of Pediatrics National Conference where he reviewed the best pediatric screening technology, including the GoCheck Kids smartphone-based photoscreener.
Gobiquity CEO Michael Brownell breaks down the mobile ophthalmology market from the viewpoint of a start-up that’s set to change how kids are diagnosed with amblyopia...
Gobiquity Mobile, an Aliso Viejo-based company, told PNN that its GoCheck Kids app is now commercially available in California prior to a national rollout this fall.
Earlier this month, Gobiquity Mobile Health introduced their flagship innovation, GoCheck Kids™, the world’s first and only pediatric photoscreening...
The GoCheck Kids application screens a young child's eyesight using the built-in camera to assess vision for refractive risk factors for amblyopia.
A new smartphone app aims to help make pediatric vision photo screening a more effective diagnostic approach...
Next month, Gobiquity Mobile Health will introduce their flagship innovation, GoCheck Kids™, the world’s first and only pediatric...
A new app available to pediatricians can screen children as young as six months old for vision problems that could lead to permanent vision loss.